Local pharmaceutical companies, doctors at hospitals and clinics, and the spa and beauty salons industries shows a lot of interest in the company’s products, Meline and Admedic. There were many inquiries about Meline and Admedic dermal filler’s procedure and indications for the reasons that the plastic filler is not popularized yet, and the consulting such as the detailed explanation and the procedure information were provided. In addition, inquiries are being made on requests for contracts for the Indonesian distributors, and it is expected to pass through gates to pioneer the one of the biggest economic power of Southeast Asia with a population of 270 million.
The company controls the quality standards of Meline and Admedic cross-linked Hyaluronic Acid Dermal Fillers to the level of the most similar to the osmotic pressure and pH concentration of the human body, so there is little rejection after injection into the human body. In addition, the hyaluronic acid crosslinking agent (BDDE), which is an essential additive in the hyaluronic acid crosslinking process which enables the hyaluronic acid to remain in the human body for a long time after injection, is a kind of toxic substance, and the remaining residual crosslinking agent (BDDE) component must be completely removed after the crosslinking process. The company has applied the number of filtration times and the period of more than twice as much as that of other companies in the process of removing this residual crosslinking agent (BDDE)which will act as a toxin in the human body. As a result of the above, the endotoxin level of Meline and Admedic, which has not been sterilized, is equal to or less than the endotoxin level of other companies that have been sterilized yet. The company sets and manages the best quality standards in the world in order to have the title of the safest dermal fillers in the world with the least side effects after the procedure. Meline and Admedic are being exported to China, Russia, Vietnam, Kazakhstan, UK, and North America, etc.